ArticleBMC infectious diseases2025
Risk factors for rifampicin-susceptible and isoniazid-resistant tuberculosis in adult patients with type 2 diabetes mellitus in Nanjing.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of risk factors for latent tuberculosis infection among type 2 diabetics: a hospital-based multicenter cross-sectional study.Frontiers in cellular and infection microbiology · 2026Article
- Whole-lung computed tomography radiomics combined with clinical features for differentiating multidrug-resistant tuberculosis from drug-sensitive tuberculosis: a retrospective multi-center study.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveGlobally, Tuberculosis(TB) with type 2 diabetes mellitus (T2DM) is becoming increasingly serious, especially the emergence of rifampicin-susceptible and isoniazid-resistant tuberculosis (Hr-TB), which increases the difficulty of treatment and the burden of disease. Therefore, this single-center retrospective cohort study analyzed risk factors of Hr-TB in adult patients with T2DM and pulmonary tuberculosis (PTB) in Nanjing to guide clinical practice and improve the long-term prognosis of patients.
methodsThe clinical data of 279 adult inpatients diagnosed with culture-positive PTB and T2DM in the Second Hospital of Nanjing from January 2019 and December 2021 were collected. According to the drug susceptibility testing (DST) results, 44 patients with Hr-TB were categorized as the Hr-TB group, while the remaining 235 patients with drug-susceptible tuberculosis (DS-TB) were classified as DS-TB group. Hierarchical logistic regression was employed for multivariate analysis to identify variables associated with Hr-TB in patients with T2DM.
resultsThere were no significant differences in age, sex, body mass index (BMI), smoking, drinking, ethnicity, education level, or comorbidities between the DS-TB and Hr-TB groups. Multivariate logistic regression analysis revealed that, history of previous tuberculosis treatment (OR = 2.348, 95%CI: 1.025 ~ 5.379, P = 0.044), poor FPG control (OR = 2.402, 95%CI: 1.208 ~ 4.776, P = 0.012), and serum iron levels ≥ 14.3µmol/l (OR = 2.808, 95%CI: 1.334 ~ 5.910, P = 0.007) are independent risk factors for Hr-TB in adult patients with T2DM in Nanjing. Within the cohort, 241 patients were Newly treatment tuberculosis patients, and among them, poor FPG control (OR = 2.296, 95%CI: 1.073 ~ 4.915, P = 0.032), and serum iron levels ≥ 14.3µmol/l (OR = 2.418, 95%CI: 1.048 ~ 5.577, P = 0.038) were identified as risk factors for Hr-TB.
conclusionPoor fasting glycemic control and serum iron levels ≥ 14.3µmol/L are independent risk factors for the development of Hr-TB in adults with T2DM and PTB, moreover, the contribution of these as risk factors were more pronounced in the newly treatment tuberculosis patients subgroup than patients with a history of previous tuberculosis treatment. History of previous tuberculosis treatment was also found to be a risk factor for Hr-TB in adults with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.